B. Riley Securities reiterated coverage on BioVie with a new price target

11/30/21 8:23:48 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIVI

Date	Price Target	Rating	Analyst
7/22/2022	$7.00	Overweight	Cantor Fitzgerald
11/30/2021	$50.00 → $27.00	Buy	B. Riley Securities